For research use only. Not for use in diagnostic procedures.
The changing landscape of the pharmaceutical drug pipeline from predominantly small molecules to an even distribution between small and large molecules has resulted in the significant optimization of analytical workflows that were typically used in the past for bioanalysis. For the purposes of bioanalytical method development, peptides are distinguished from proteins based on size, and quantifying levels of protein and peptide therapeutics with increased confidence is an extremely important part of a successful biotherapeutic drug development.
SCIEX continues its tradition of developing robust, reproducible and sensitive bioanalytical assays for all molecule types. From small molecule drug candidates to peptide or protein therapeutics to oligonucleotide therapeutics and antibody drug conjugates, SCIEX provides a robust solution for every challenge in bioanalysis. In DMPK or in regulated bioanalysis, the optimized combination of state of the art hardware QTRAP® or TripleTOF® Systems, ground-breaking software solutions, and an expert application support team provide a world-class solution.